Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

DKTK Freiburg: Physicists simplify production of hypersensitive contrast agent for cancer diagnostics

No. 10 | 06/03/2017 | by AM

To make even the smallest tumor clusters and other pathological metabolic processes visible with the help of magnetic resonance imaging (MRI): Physicists from the German Cancer Consortium (DKTK) at the University Hospital of Freiburg have come one step closer to this goal. The scientists used the highly sensitive hyperpolarization MRI, which uses magnetic contrast agents to be several times more sensitive than classic MRIs. The Freiburg researchers managed to radically simplify the production of such contrast agents, which had previously been both very complicated and expensive. This will allow the production of contrast agents that can be used to observe pathological metabolic processes in cancer in real time. The production procedure of these contrast agents has been published in the journal "Nature Communications."
The DKTK is made up of the German Cancer Research Center (DKFZ) in Heidelberg as the core location, along with renowned oncology departments of universities in various partner locations across Germany.

© DKFZ / Tobias Schwerdt

"With this process we have named SAMBADENA we are able to make the contrast agent for hyperpolarization MRIs much cheaper, simpler and faster than previously possible," said the project leader Dr. Jan-Bernd Hövener, Emmy Noether research group leader in the Radiology-Medical Physics clinic of the University Hospital Freiburg. Along with his doctorate students Andreas Schmidt and Stephan Berner, he has achieved an important step in the production of hyperpolarized contrast agents. "For the first time it is possible to produce the injection solution with the contrast agent right where it is needed, in the MRI scanner, within a matter of seconds," says principal author Andreas Schmidt.

With the hyperpolarization MRI, a magnetically marked contrast agent is injected into the body, from where it sends out signals which are significantly stronger than would be possible in a classic MRI. This can greatly increase the sensitivity of the MRI, and thus help gather information crucial for diagnosis and therapy. Previously, liquid hyperpolarized contrast agents were chiefly produced with dynamic nuclear polarization (DNP). For this method, already used on patients, scientists require a complex device that costs up to 2.5 million Euros. The new method opens up the opportunity to drastically decrease these costs. "We hope that this will help further develop the use of hyperpolarization MRI," says Jan-Bernd Hövener, who researches in the radiotherapy and imaging department of the German Cancer Consortium, and is part of the EU sponsored research network EUROPOL-ITN.

By creating the contrast agent directly in the MRI device, researchers will soon presumably be able to use molecules as contrast agents, whose marking would otherwise have disintegrated during transportation to the MRI device. "We are now intensively working on using SAMBADENA on bio molecules which naturally occur in the body. Their deconstruction or reconstruction could then be observed in real time," says Jan-Bernd Hövener. Early unpublished results point in this direction. Since cancer cells often exhibit a different metabolism, an increased or decreased deconstruction of the contrast agent could point to cancer tissue. This would allow for early identification of metastases and the ability to characterize tumors more accurately. It also seems possible to use the change in cancer metabolism to detect earlier whether a therapy is working or not. "A further advantage is that endogenous substances do not cause allergic reactions, which is sometimes the case with previous MRI contrast agents," says Jan-Bernd Hövener. A series of suitable contrast agents are to be developed in subsequent studies.

Schmidt, A.B. et. al.: Liquid-state carbon-13 hyperpolarization generated in an MRI system for fast imaging. In: Nature Communications doi:10.1038/ncomms14535 (http://www.nature.com/articles/ncomms14535)

A video for the press release is available at:
https://www.youtube.com/watch?v=N2Ekdk09fl4

How does the hyperpolarization MRI work and how can patients benefit from it? A video of the Hövener research group explains the imaging method with magnetic contrast agents.

* The German Cancer Consortium (DKTK) is a joint long-term initiative involving the German Federal Ministry of Education and Research (BMBF), participating German states and the German Cancer Research Center (DKFZ) and was established as one of six German Health Research Centres (DZGs). As DKTK's core center the DKFZ works together with research institutions and hospitals in Berlin, Dresden, Essen/Düsseldorf, Frankfurt/Mainz, Freiburg, Munich, Heidelberg and Tübingen to create the best possible conditions for clinically oriented cancer research. The consortium promotes interdisciplinary research at the interface between basic research and clinical research, as well as clinical trials for innovative treatments and diagnostic methods. Another key focus of the consortium's work is on developing research platforms to speed up the application of personalized cancer treatments and to improve the diagnosis and prevention of cancer.

More information is available at www.dktk.org

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS